Loratadine


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Allergic conditions
Adult: 10 mg once daily or 5 mg bid.
Child: 2-12 years <30 kg: 5 mg once daily; >30 kg: 10 mg once daily. >12 years Same as adult dose.
Renal impairment:
CrCl (ml/min)Dosage Recommendation
<30 10 mg every other day.
Hepatic impairment: Severe: Initially, 10 mg every other day.
Administration
May be taken with or without food.
Special Precautions
Severe hepatic and renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: Headache, somnolence, drowsiness, fatigue, nervousness. Cardiac disorders: Palpitation, tachycardia, hypotension. Gastrointestinal disorders: Dry mouth, abdominal pain, nausea, vomiting, diarrhoea, gastritis. Hepatobiliary disorders: Jaundice, hepatitis, hepatic necrosis. Investigations: Elevated liver enzymes, weight gain. Metabolism and nutrition disorders: Increased appetite. Nervous system disorders: Dizziness. Skin and subcutaneous tissue disorders: Rash, alopecia.
Overdosage
Symptoms: Somnolence, tachycardia, drowsiness, headache. Management: Symptomatic and supportive treatment. May administer activated charcoal and may perform gastric lavage.
Drug Interactions
May increase plasma concentrations with ketoconazole, fluconazole, erythromycin, clarithromycin, cimetidine.
Food Interaction
Food delays time to peak plasma concentration and increases bioavailability. Increase risk of CNS depression with alcohol.
Lab Interference
May diminish the wheal and flare reactions to skin test antigens.
Action
Loratadine, a piperidine derivative, is a long-acting, non-sedating antihistamine which selectively inhibits histamine H1-receptors on effector cells.
Onset: 1-3 hours.
Duration: >24 hours.
Absorption: Rapidly and well absorbed from the gastrointestinal tract. Food delays time to peak plasma concentration and increases bioavailability. Time to peak plasma concentration: Approx 1-1.5 hours (loratadine); approx. 1.5-3.7 hours (desloratadine).
Distribution: Enters breast milk. Volume of distribution: 119 L/kg. Plasma protein binding: Approx 97-99% (loratadine); approx 73-76% (desloratadine).
Metabolism: Extensively undergoes first-pass metabolism in the liver via CYP2D6 and CYP3A4 to desloratadine as the active metabolite.
Excretion: Via urine (40%); faeces (approx 40% as metabolites). Elimination half-life: 8.4 hours (loratadine); 28 hours (desloratadine).
Storage
Oral: Store between 20-25°C. Protect from heat, light and moisture.
CIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AX13 - loratadine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by CIMS based on loratadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in